
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Hldgs is supported by a durable WAKIX franchise, with 3Q26 net revenue expected around $275M and 2026 guidance reaffirmed at $1.00B–$1.04B, signaling continued commercial strength in narcolepsy. The company’s positive outlook is also driven by a visible pipeline across rare neurological diseases, including BP-205, EPX-100, Zygel, and pitolisant programs, which can diversify growth beyond one product. Leadership continuity through the planned 2027 CEO transition, plus a strong June cash balance of $962.5M, supports execution, while the upcoming 4Q26 BP-205 data readout and ongoing exclusivity efforts provide additional catalysts.
Bears say
Harmony Biosciences Hldgs is facing a fundamentally fragile growth profile because WAKIX remains the core revenue driver while the sodium oxybate market can become more competitive, new patient adds may slow more than expected, and earlier-than-expected generic pitolisant competition could pressure the franchise. The pipeline does not sufficiently offset that concentration risk, as several programs across PWS, DM1, DS/LGS, Fragile X syndrome, and EPX-100 still depend on clinical success and commercialization execution, creating meaningful binary downside. Even under a 12% discount rate and 6.0x terminal multiple, the valuation framework is highly sensitive to these uncertainties, with litigation, reimbursement, pricing, and competitor risks further threatening the approximately $3.2 billion firm value assumption.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Harmony Biosciences Holdings (HRMY) Forecast
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares